ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

CGEN Compugen Ltd

1.89
-0.02 (-1.05%)
After Hours
Last Updated: 22:50:31
Delayed by 15 minutes
Share Name Share Symbol Market Type
Compugen Ltd NASDAQ:CGEN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.02 -1.05% 1.89 1.85 1.89 1.94 1.84 1.94 392,094 22:50:31

Compugen First Quarter 2013 Conference Call Scheduled for Thursday, April 25, 2013 at 10:00 AM EDT

18/04/2013 3:47pm

Business Wire


Compugen (NASDAQ:CGEN)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more Compugen Charts.

Compugen Ltd. (NASDAQ: CGEN) today announced that the Company will host a conference call at 10:00 AM EDT on Thursday, April 25, 2013 to review first quarter 2013 results. The quarterly results will be released on the Company’s website (www.cgen.com), prior to the conference call.

To access the conference call, please dial 1-888-668-9141 from the US, or + 972-3-9180610 internationally. The call will also be available via live webcast through Compugen’s website, located at the following link.

A replay of the conference call will be available approximately two hours after the completion of the live conference call. To access the replay, please dial 1-888-782-4291 from the US or +972-3-9255-918 internationally. The replay will be available through April 29, 2013.

About Compugen

Compugen is a leading drug discovery company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of immunology and oncology. The Company utilizes a broad and continuously growing integrated infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology capabilities for the in silico (by computer) prediction and selection of product candidates, which are then advanced in its Pipeline Program. The Company's business model includes collaborations covering the further development and commercialization of selected product candidates from its Pipeline Program and various forms of research and discovery agreements, in both cases providing Compugen with potential milestone payments and royalties on product sales or other forms of revenue sharing. In 2012, Compugen established operations in California for the development of oncology and immunology monoclonal antibody therapeutic candidates against Compugen drug targets. For additional information, please visit Compugen's corporate website at www.cgen.com

1 Year Compugen Chart

1 Year Compugen Chart

1 Month Compugen Chart

1 Month Compugen Chart